Loading market dashboard
VictoryShares US EQ Income Enhanced Volatility Wtd ETF
CDCFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
CLPS Incorporation Restructures R&D Architecture, Introduces AI Rainstorm Factory Development Model PR Newswire
WHO-flagged Ebola outbreak and rising hantavirus exposure risks underscore growing institutional demand for scalable, hospital-grade decontamination solutions across healthcare, hospitality, transportation, and agricultural infrastructure. WHO-flagged Ebola outbreak and rising hantavirus exposure risks underscore growing institutional demand for scalable, hospital-grade decontamination solutions across healthcare, hospitality, transportation, and agricultural infrastructure.
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT). This certifies that the Atellica IM TSTII immunoassay's test results are equivalent to high performance liquid chromatography coupled with tandem mass spectrometry, which is regarded as the gold‑standard analytical approach [1,2]. The Atellica IM TSTII assay, available on the Atellica IM and Atellica CI Analyzers, is the only fully automated immunoassay to achieve CDC HoSt-TT certification, which it has maintained continuously since 2019 [3]. An evaluation of the assay's performance was recently published in The Journal of Clinical Endocrinology & Metabolism.
